

Letter to the Editor

Effect of *CYP3A53 on asthma control among children treated with inhaled beclomethasone***To the Editor:*

Inhaled glucocorticoids are a primary therapy for controlling persistent asthma symptoms.¹ However, approximately 30% of patients continue to experience poor symptom control.² Criteria to identify patients who might respond more favorably to a specific inhaled glucocorticoid could be beneficial.³

We previously identified a genetic variant in the cytochrome P450 3A4 enzyme (*CYP3A4**22) that was associated with improved asthma control among children treated with inhaled fluticasone.⁴ Patients with the *CYP3A4**22 allele have been reported to feature 1.6- to 6.3-fold lower *CYP3A4* mRNA expression and enzyme activity in the liver.⁵ Fluticasone is efficiently metabolized by *CYP3A4* and is a potent mechanism-based inhibitor of *CYP3A5* and to a lesser extent *CYP3A4*.⁴ It was hypothesized that decreased levels of *CYP3A4* combined with inhibition of *CYP3A5* by fluticasone may extend the half-life of fluticasone within lung cells and in the systemic circulation, thereby increasing its therapeutic effectiveness. We speculated that similar processes may occur for other inhaled glucocorticoids.⁴

Beclomethasone is a commonly prescribed inhaled glucocorticoid that features potent anti-inflammatory effects and effectively reduces bronchial hyperresponsiveness.⁶ In this study, a convenience sample of beclomethasone-treated children aged 2 to 17 years with a physician-confirmed diagnosis of asthma were recruited at Primary Children's Hospital (Salt Lake City, Utah). Details of the study design and genotyping have been described previously.⁴ Briefly, saliva samples were collected and tested for 9 single nucleotide polymorphisms (SNPs) in *CYP3A4*, *CYP3A5*, and *CYP3A7*. Demographic and clinical data were obtained through patient and/or parent survey and medical record abstraction. Asthma control was assessed using a questionnaire modified from the National Heart, Lung, and Blood Institute.^{4,7} Asthma control scores were analyzed as a numeric variable that

ranged from 0 (well controlled) to 15 (poorly controlled). Logistic regression models were developed in R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) to assess the effect of *CYP3A* polymorphisms on asthma control with inhaled beclomethasone. The Bonferroni correction was applied to adjust for 3 pairwise group comparisons (3 SNPs) for each *CYP3A* enzyme. The daily dose of beclomethasone dipropionate ($\mu\text{g}/\text{d}$) was evaluated as a covariate in the regression analyses; however, the dose did not significantly alter the β coefficient in any of the models tested ($P > .5$) and was not retained in final analyses.

A total of 64 beclomethasone-treated children with asthma were recruited. The median age was 8 years (interquartile range, 5.5-11 years) and 42 (66%) were boys. The median asthma control score was 5.5 (interquartile range, 4-8). Saliva was collected from all participants, and *CYP3A* genotyping results are presented in Table 1. Allelic variants in *CYP3A4* and *CYP3A7* were not significantly associated with asthma control scores, following adjustment for multiple comparisons. Two SNPs in *CYP3A5* were associated with improved asthma control. The *CYP3A5**3/*3 genotype was associated with a 2.7-point (95% CI, 0.9-4.6) improvement in the asthma control score when compared with patients with *CYP3A5**1/*1 or *CYP3A5**1/*3 genotypes (Fig 1). As previously reported, the *CYP3A5**1D SNP (rs15524) was found in the same patients carrying the *CYP3A5**3 SNP (rs776746), presumably explaining the concurrent association with asthma control.^{8,9} The *CYP3A5**3 SNP was found to be in complete linkage disequilibrium with the *CYP3A5**1D SNP (Hedrick's multiallelic $D' = 1.0$).¹⁰

Using recombinant *CYP3A* enzymes, we have previously shown that beclomethasone is efficiently inactivated by *CYP3A5*.⁶ Several *CYP3A5* genetic polymorphisms have been shown to alter mRNA expression and enzyme function, with the most common being *CYP3A5**3, which codes for an inactive form of *CYP3A5*.⁸ A majority of whites are homozygous for *CYP3A5**3 and therefore do not express active *CYP3A5*, whereas other racial and ethnic groups commonly express the *CYP3A5**1 allele, which codes for an active form of *CYP3A5*.⁹ However, it is important to note that in this study, 88% of the individuals with the

TABLE 1. Association of *CYP3A* genetic polymorphisms and asthma control scores among 64 children receiving daily inhaled beclomethasone dipropionate

Polymorphism	Reference SNP (rs no.)	Association with asthma control scores (<i>P</i> value)*	Reference allele frequency	Variant allele frequency
<i>CYP3A4</i>				
<i>CYP3A4</i> *22	rs35599367	NA	1.00	0.00
<i>CYP3A4</i> int 7	rs2246709	.39	0.60	0.40
<i>CYP3A4</i> int 7	rs4646437	.10	0.70	0.30
<i>CYP3A5</i>				
<i>CYP3A5</i> *3	rs776746	.01	0.66	0.34
<i>CYP3A5</i> *6	rs10264272	.57	0.98	0.02
<i>CYP3A5</i> *1D	rs15524	.01	0.66	0.34
<i>CYP3A7</i>				
<i>CYP3A7</i>	rs2687133	.13	0.84	0.16
<i>CYP3A7</i> *2	rs2257401	.14	0.81	0.19
<i>CYP3A7</i> 6 nt 5' of ex 14	rs2740565	.07	0.77	0.23

No patients identified with the variant allele (NA). All SNPs were in Hardy-Weinberg equilibrium.

*Bonferroni adjustment for multiple comparisons.




FIG 1. Asthma control scores among 64 children receiving inhaled beclomethasone, stratified by *CYP3A5* genotype. Two patients featured the *CYP3A5**1/*1 genotype and are represented as solid black circles. Asthma control scores are scaled from 0 (well controlled) to 15 (poorly controlled).

*CYP3A5**1/*1 or *1/*3 genotype self-reported their race as white, demonstrating the importance of genetic testing when variations in *CYP3A* genotypes are considered as a potential basis for personalizing therapy.

*CYP3A5**1D is found in the 3'-untranslated region (UTR) of the *CYP3A5* gene, although its effect on *CYP3A5* function has not been established. It is possible that this SNP may influence the efficacy of beclomethasone treatment; however, previous studies have found that the *CYP3A5**1D allele was identified only in those patients who had the *CYP3A5**3 allele.^{8,9} In this study, all patients who were homozygous for the *CYP3A5**1D SNP (rs15524) were also homozygous for the *CYP3A5**3 SNP (rs776746). Therefore, the relative contributions of these SNPs to the clinical effects we observed could not be differentiated, although it is well known that *CYP3A5**3 causes an alternative splicing event that results in nonfunctional *CYP3A5* protein. Additional studies are needed to clarify the role of *CYP3A5**1D and its effect(s), if any, on the expression and function of *CYP3A5*. Based on the current state of the field, the current data support the hypothesis that the relationship between improved asthma control scores among beclomethasone-treated children with the *CYP3A5**1D/*1D genotype is ultimately due to the inactivation of *CYP3A5* caused by the *CYP3A5**3 SNP.

The physiological basis for the association between improved asthma control with beclomethasone and *CYP3A5**3 is not completely understood. This inactivating SNP abolishes *CYP3A5* activity both in the lung and in the liver.⁸ Reduced

pulmonary and hepatic enzyme activity is likely to prolong the presence of active beclomethasone within the airway, thereby increasing the duration of its anti-inflammatory effects. In addition, further investigation is warranted to determine whether diminished *CYP3A5* activity may be associated with higher systemic concentrations of beclomethasone, which has the potential to increase the risk of adverse effects, including suppression of the hypothalamic-pituitary-adrenal axis.

Interpretation of our findings should be considered in light of several limitations. First, the precision of our effect estimates is limited by our sample size ($n = 64$). Second, it was not possible to directly measure *CYP3A5* expression or tissue-specific activity; however, these studies are ongoing. Last, we did not obtain pulmonary function tests because standard spirometry measurements require a degree of patient cooperation that is difficult to achieve in the youngest of children.

The clinical relevance of this observed association requires further mechanistic explanation and additional study with larger sample sizes. Nevertheless, these data support an association between improved asthma control with inhaled beclomethasone and the loss of function *CYP3A5**3 allele and are consistent with our earlier work in which asthma control was found to be improved among children treated with fluticasone who had a genotype consistent with reduced *CYP3A4* activity.⁴ When genetic testing is clinically available, these findings may be useful in selecting an appropriate therapeutic agent for patients who do not achieve optimal control with their currently prescribed inhaled glucocorticoid.

We thank Bradley W. Thomas and Amber Bagherian for their technical support.

Chris Stockmann, MSc^{a,b}
Christopher A. Reilly, PhD^b
Bernhard Fassl, MD^a
Roger Gaedigk, PhD^c
Flory Nkoy, MD, MPH, MS^a
Bryan Stone, MD^a
Jessica K. Roberts, PhD^a
Derek A. Uchida, MD^a
J. Steven Leeder, PharmD, PhD^c
Catherine M. T. Sherwin, PhD^a
Michael G. Spigarelli, MD, PhD^a
Garold S. Yost, PhD^{b,†}
Robert M. Ward, MD^{a,b}

From ^athe Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah; ^bthe Department of Pharmacology/Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah; and ^cthe Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, Mo. E-mail: Robert.Ward@hsc.utah.edu.

†Deceased.

This project was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant no. R01 HD060559). C.S. is supported by the American Foundation for Pharmaceutical Education's Clinical Pharmaceutical Sciences Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. Additional support was provided by the Primary Children's Medical Center Research Foundation and the Center for Clinical and Translational Sciences (grant no. CTSA 5UL1RR025764-02).

Disclosure of potential conflict of interest: C. Stockmann has received research support from the National Institutes of Health-Eunice Kennedy Shriver National Institute of Child Health and Human Development and the American Foundation for Pharmaceutical Education. F. Nkoy has received research support from the National Institutes of Health-Eunice Kennedy Shriver National Institute of Child Health and Human

Development and the Patient-Centered Outcomes Research Institute (51002874) and has a pending patent application for electronic Asthma Tracker. C. A. Reilly, B. Fassl, R. Gaedigk, B. Stone, J. K. Roberts, D. A. Uchida, J. S. Leeder, C. M. T. Sherwin, M. G. Spigarelli, and R. M. Ward have received research support from the National Institutes of Health-Eunice Kennedy Shriver National Institute of Child Health and Human Development.

REFERENCES

1. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. *N Engl J Med* 2011;365:1173-83.
2. Szeffler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. *J Allergy Clin Immunol* 2005;115:233-42.
3. Drazen JM. A step toward personalized asthma treatment. *N Engl J Med* 2011;365:1245-6.
4. Stockmann C, Fassl B, Gaedigk R, Nkoy F, Uchida DA, Monson S, et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. *J Pediatr* 2013;162:1222-7, 1227.e1-2.
5. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics J* 2011;11:274-86.
6. Roberts JK, Moore CD, Ward RM, Yost GS, Reilly CA. Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. *J Pharmacol Exp Ther* 2013;345:308-16.
7. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. *J Allergy Clin Immunol* 2007;120:S94-138.
8. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* 2001;27:383-91.
9. Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. *Xenobiotica* 2006;36:1191-200.
10. Hedrick PW. Gametic disequilibrium measures: proceed with caution. *Genetics* 1987;117:331-41.

<http://dx.doi.org/10.1016/j.jaci.2015.02.009>